PRTH Investors Have the Opportunity to Join Investigation of Priority Technology Holdings, Inc. with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$PRTH—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims... Read more.
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater... Read more.
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater... Read more.
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe... Read more.
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
Hypercortisolism identified in 27.3 percent of patients with resistant hypertension REDWOOD CITY, Calif.–(BUSINESS WIRE)–Corcept Therapeutics Incorporated... Read more.
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16,... Read more.
Anumana Secures FDA Clearance for First-of-Its-Kind ECG-AI Algorithm for Early Detection of Pulmonary Hypertension
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its... Read more.
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
– Patients with severe hypertriglyceridemia (sHTG) achieved an 83% median reduction in triglycerides (TG), with 96% of patients achieving TG levels below 500 mg/dL,... Read more.
IBRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO–(BUSINESS WIRE)–$IBRX #IBRX–The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio,... Read more.
ZIVO Bioscience Provides Special Letter to Shareholders
TROY, Mich.–(BUSINESS WIRE)–ZIVO Bioscience, Inc. (OTCQB: ZIVO), today issued the following letter to shareholders from Chairman, President and Chief... Read more.